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Summary
This report examines structural changes in a highly
mutated, clinical multidrug-resistant HIV-1 protease,
and the crystal structure has been solved to 1.3 A˚ res-
olution in the absence of any inhibitor. This protease
variant contains codon mutations at positions 10, 36,
46, 54, 62, 63, 71, 82, 84, and 90 that confer resistance
to protease inhibitors. Major differences between the
wild-type and the variant include a structural change
initiated by the M36V mutation and amplified by addi-
tional mutations in the flaps of the protease, resulting
in a ‘‘wide-open’’ structure that represents an opening
that is 8 A˚ wider than the ‘‘open’’ structure of the wild-
type protease. A second structural change is triggered
by the L90M mutation that results in reshaping the 23–
32 segment. A third key structural change of the prote-
ase is due to the mutations from longer to shorter
amino acid side chains at positions 82 and 84.
Introduction
The causative agent for AIDS, the human immunodefi-
ciency virus (HIV), has become one of the most challeng-
ing infectious entities known to humanity. About 42 mil-
lion people throughout the world are infected with HIV,
and an estimated 14,000 are infected per day worldwide
(UNAIDS, 2002).
Combination antiretroviral therapy, or HAART, is key
to the medical management of HIV infection, and the
goal of combination antiviral therapy is to suppress
HIV replication in the patient for as long as possible.
Eradication of the HIV infection is not possible with cur-
rently available HAART regimens.
Protease inhibitors are a potent and selective class
of antiviral drugs, and they target the HIV-1 protease
*Correspondence: kovari@med.wayne.edu
5 These authors contributed equally to this work.enzyme required for the cleavage of the Gag-Pol viral
polyprotein. Drug resistance is probably the most im-
portant factor influencing failure of present treatment
approaches to HIV infection. Numerous inhibitors of
HIV-1 protease have been described in an attempt to
block viral proteolytic maturation. Clinical studies of
several HIV-1 protease inhibitors have established that
these compounds can profoundly suppress the levels
of virus in the blood (Holodniy et al., 1993; Katzenstein
and Holodniy, 1995). However, treatment with these
drugs, as with the reverse transcriptase inhibitors, se-
lects for resistant viral variants (Deutsch et al., 1994),
and the protease gene mutations associated with resis-
tance to inhibitors are reviewed periodically (Johnson
et al., 2003).
The rapidly evolving HIV-1 protease requires contin-
ued attention as a drug target for rational drug design
due to its essential role in the proteolytic processing
of the viral Gag and Gag-Pol polyproteins (Tomasselli
et al., 1990). Viral progeny that do not have a func-
tional protease are noninfectious (Kohl et al., 1988),
and small-molecule inhibitors of the protease efficiently
block replication of HIV in vitro (Huff, 1991). With the de-
velopment and distribution of protease inhibitors for the
treatment of HIV, there has been an increase in the num-
ber of resistance mutations within proteases, which di-
minishes the success of protease inhibitors (Baldwin
et al., 1995; Coffin, 1995; Gatanaga et al., 2002; Jacob-
sen et al., 1995; King et al., 1995; Patick et al., 1995;
Ridky and Leis, 1995; Rose et al., 1996; Weber et al.,
2002).
According to the active site expansion model, HIV-1
protease multi-drug resistance is associated with a se-
ries of conformational changes of the HIV-1 protease
leading to an expanded active site cavity and, as a result,
a diminished binding of the protease inhibitor (Logsdon
et al., 2004). It is important to note that the active site
expansion model is consistent with both the substrate
envelope hypothesis (Prabu-Jeyabalan et al., 2002a,
2002b, 2003; Wu et al., 2003) and thermodynamic mea-
surements of ligand binding (Kurt et al., 2003). In the
substrate envelope model, Dr. Schiffer and coworkers
have determined a series of crystal structures of HIV
protease-substrate complexes, and the authors pro-
pose a hypothesis in which inhibitors that fit within the
substrate envelope of HIV-1 protease may be more ef-
fective and less susceptible to drug resistance muta-
tions. Microcalorimetric measurements by Freire et al.
indicate that drug-resistant mutants lower the affinity
of the licensed inhibitors by two or three orders of mag-
nitude (Leavitt and Freire, 2001; Ohtaka et al., 2002;
Velazquez-Campoy et al., 2000, 2001).
The focus of this work is to investigate the structural
changes in the HIV-1 viral protease that render protease
inhibitors unable to inhibit viral replication. Protease in-
hibitors currently in use were designed to bind to pro-
teases with closed flaps. In this study, we used X-ray
crystallographic analysis and report a 1.3 A˚ resolution
‘‘wide-open’’ structure of a multidrug-resistant HIV-1
protease clinical isolate.
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Overall Differences in the Multidrug-Resistant
HIV-1 Protease
The HIV-1 protease variant, MDR 769, contains codon
mutations at positions 10, 36, 46, 54, 62, 63, 71, 82, 84,
and 90 that are known to confer drug resistance to
U.S. FDA-approved protease inhibitors. One of the strik-
ing differences between the wild-type and the MDR 769
HIV-1 protease is a very large conformational change in
the flap region with a movement of more than 8 A˚ relative
to the native structure. The wild-type structure (3PHV),
known as the ‘‘open’’ form, crystallizes in space group
P41212 with cell constants very similar to those of the
MDR 769 mutant, which crystallizes in space group
P41 (a = 52.24 A˚ versus 45.04 A˚ and c = 107.12 A˚ versus
105.77 A˚, respectively). Figure 1 illustrates the relative
movement in the amino acid Ca atoms along with the
crystallographic temperature factor B values of the
multidrug-resistant HIV-1 protease relative to the wild-
type crystal structure. Figure 2 shows an overlapping
ribbon diagram of MDR 769 and the wild-type structure
(3PHV). Since the crystal structures have very close
environments—virtually identical in places—one cannot
invoke crystal packing as the reason for these confor-
mational differences. It is clear from Figure 2 why we
refer to this MDR structure as the ‘‘wide-open’’ form of
HIV protease.
The crystallographic 2-folds in the native structure,
which orient two of the monomers in the asymmetric
unit into a functional dimer, have become local 2-folds
in our structure. In performing the superposition (LSQAB
from CCP4 V4.2.2 [Fitzgerald, 1994]), we used only the
hinge region of the structure, and only residues 3–6,
24–28, and 67–69 were used to calculate the least
squares superposition. The rms deviation of the Cas
atoms for the hinge region residues is 0.52 A˚, versus
1.86 A˚ if all of the Cas atoms of the protease are used.
Therefore, we consider the deviations greater than 1 A˚,
or roughly twice the rms deviation Ca, as significant.
Reshaping the HIV-1 Protease, Resulting
in the ‘‘Wide-Open’’ Structure
The high-resolution structure of a MDR HIV-1 protease
(isolate 769) permits the examination of structural
changes relative to the wild-type, and it is correlated
with the drug-resistance properties of this protease var-
iant (Palmer et al., 1999). The largest observed structural
changes affect the amino acid sequence from residue 36
through 64 (Figure 2), resulting in a dramatic ‘‘opening’’
of the flaps.
Figure 3 shows the symmetric movement of the flaps
away from the ‘‘open’’ form in the wild-type to the ‘‘wide-
open’’ form in the MDR protease. The ‘‘open’’ form is
stabilized at the tips of the flaps at residues I50–G51
by four van der Waals (vdW) contacts and two hydrogen
bonds. The hydrogen bonds are between pairs of amide
nitrogens (G51A-N donor, G51B-N acceptor, or vice
versa, and I50A-N donor, I50B-N acceptor). The hydro-
gen bonding pairs are separated by 3.1 A˚ (the G51
pair) and 2.8 A˚ (the I50 pair). The only way for this to hap-
pen is for one of the peptides to be in the form of an enol
tautomer (Ca-(OH)C = N-Ca) and the other to be in the
form of a keto tautomer (Ca-(O = )C-N(H)-Ca). Only underthese circumstances can there be a donor nitrogen atom
with a hydrogen and acceptor nitrogen atom having a
pair of electrons to share.
The new position for each flap produces a single vdW
interaction, albeit a very good one, at a distance of 3.6 A˚
for each chain. This contact occurs between I50 Cd1 of
chain A and P81 Cg of chain B, and vice versa. The con-
sequence of this is that P81 is displaced 2.6 A˚, pulling
A82, itself a mutation, 1.2 A˚ from its position in the native
structure.
Figure 4 illustrates a fragment in the chain of events
leading to the rearrangement in the flaps of the HIV-1
protease. The first mutation in this region, M46L, dis-
places the backbone over 2 A˚ simply because a vdW
contact between the side chains of M36 and I15 (3.1 A˚)
is not present in the mutated species. The effect of the
M36V mutation has an impact on amino acid residues lo-
cated at a distance. It extends three residues toward the
N terminus and is extensively propagated in the forward
direction (toward the C terminus). The Cg2 of V36 (Fig-
ure 4) makes a new vdW contact with the Cd2 of L38
(3.7 A˚). These two side chain atoms form two new vdW
contacts with G16 Ca (3.9 and 3.8 A˚, respectively), mov-
ing the G16 loop over 2 A˚. In this case, the forces acting
on the two sections of chain are reciprocal in nature. Not
only is G16 displaced by 2 A˚ toward L38, but the entire
G40 loop (Figure 4), from M36V to the next mutation,
M46L, is shifted severely by 2.9 A˚ in the vicinity of resi-
due 46. The polymorphic M36V mutation contributes
to resistance when present in combination with one or
more resistance mutations. The result is drug resistance
to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir,
ritonavir, and saquinavir (Stanford HIV Drug Resistance
Database, http://hivdb.stanford.edu; Shafer et al., 1999).
The G40 loop is not only acted upon by the M36V sub-
stitution (Figure 4). The side chain of V36 (Cg1) makes an
additional vdW contact with V77 Cg1 (3.7 A˚), which, ac-
companied by the I50-P80 interaction, shifts the main
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Figure 1. Changes in Ca and B Values for HIV-1 MDR 769 Protease
Relative to the Wild-Type Structure
The protease amino acid residues are represented on the x axis, and
Ca (A˚) and B (A˚
2) are shown on the double y axis. The differences in
atomic positions for the Ca atoms of MDR 769 HIV-1 protease and
the wild-type protease are shown (solid histogram). The temperature
factors (B values) for the corresponding residues are shown by the
striped histogram.
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1889Figure 2. Structural Differences between
MDR 769 HIV-1 Protease and the Wild-Type
The dark-red ribbon indicates the MDR 769
protease variant, and the red ribbon repre-
sents the wild-type protease. The mutated
MDR amino acid side chains are light blue.
Orange, highlighted mutated residues are hy-
drophilic, and the sulfur-containing residue,
M90, is highlighted in yellow. A single sodium
ion is indicated as a yellow sphere.chain containing R57 by over 2 A˚. Continuing with the
domino effect, R57 is in a stretch of b sheet that forms
hydrogen bonds to the G40 loop at K45. These multiple
contacts all contribute to the overall conformational
change in the mutant, and they were all started by a sim-
ple methionine-to-valine substitution at position 36 in
a particularly vulnerable section of the chain.
The MDR patient isolate also contains the M46L muta-
tion located in the flap region of the structure that has
virtually no interaction with the rest of the protein, ex-
cept for the very tips of the flap. From about residues
46–55, the flap region is composed of an antiparallel
b sheet, with residue I50 at the tip in a Type II b turn. Con-
sequently, all of the side chains are pointing either above
or below the plane of the b sheet into the solvent.
The analysis of the 46–55 segment reveals the impact
of deleted side chain atoms. The wild-type Sd atom ofmethionine at M46 forms two excellent vdW contacts
with K55 Ca and Cg (3.5 and 3.3 A˚, respectively). When
these atoms disappear due to a mutation in MDR 769,
completely new interactions are formed in the b sheet.
In particular, the interactions twist the b sheet in such
a way that M46L Cb can make a vdW contact with F53
Cb (4.0 A˚). The side chain of F56 then reorients itself so
that F53 Cz can form a new vdW contact with G49 Ca
(3.6 A˚).
The outcome of this chain of events is that once a sin-
gle mutation is in place, an additional mutation at a favor-
able location could then further contribute to any devia-
tions that might be advantageous to the organism. We
refer to this as successive mutational reinforcement.
The next mutation present in the MDR isolate is the
I54V substitution. In the native structure, the side chain
of I54 is pointed out into the solvent and makes noFigure 3. Stereodiagrams of Water Mole-
cules Forming a Network Bridge between
the Flaps of the HIV-1 MDR 769 Protease
The gray ball-and-stick diagram represents
the MDR protease, and the green ball-and-
stick diagram is the wild-type protease. Up-
per panel: blue spheres represent the water
molecules, and the hydrogen bond scaffold-
ing is represented in red. Lower panel: com-
parison between the MDR 769 variant and
the wild-type protease in green. Long, black
arrows represent movement between the
variant and the wild-type flaps. The short ar-
row (magenta) represents new van der Waals
contacts present in MDR 769 protease.
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1890Figure 4. The Impact of the M36V Substi-
tution
A severe chain shift produced by a single mu-
tation is illustrated (native in solid green,
769MDR in yellow). The substitution of valine
for methionine at position 36 has lost a single
van der Waals (vdW) contact between Met-36
Sd and Ile-15 Cg1 (green spheres). The entire
chain moves so that a new vdW contact can
form between Leu-38 Cd2 and a repositioned
Ile-15 Cg1 (yellow spheres).contacts whatsoever. The valine substitution leads to
improved vdW contacts with K55 O and V56 Cg1 (3.8 A˚
and 4.0 A˚, respectively). These added contacts are
among those responsible for getting the flaps to shift
by more than 8 A˚.
By now, the chain trace has essentially shifted relative
to the wild-type. Carbonyl groups are falling where Cas
should be, and where the Cas amide nitrogen atoms
are in the native structure, and so on. However, from
the I62V position, the deviations are starting to diminish
(Figure 1).
Figure 5 shows a close-up of the interactions. We
computed the surface area covered by intermolecular
symmetry contacts (Richards, 1985) for both the wild-
type and MDR 769. The wild-type contact area has pri-
Figure 5. Crystal Packing Close-Up at the I50 Loop Region
A crystal packing close-up shows the symmetry-related residues
(green for one monomer, yellow for the other) that are within contact
distance (4 A˚) of the I50 loop (standard colors) for MDR 769 and the
wild-type HIV protease. The I50 loop forms new contacts with resi-
dues in the mutated I40 loop (M36V, S37N, M46L), Q61 (next to
I62V and L63P), and I72 (adjacent to A71V). Residues T91–I93, which
are in the region of the L90M mutation, complete the contact envi-
ronment.mary interactions with symmetry-related residues at
T91–G94 and I72, with a total contact area of 1,222 A˚2.
In MDR 769, that area increases to 2,621 A˚2, primarily
due to new interactions with residues P39–R41 and
Q61. Of particular interest is that the new contacts are
all in regions that are within, or adjacent to, mutations
themselves. In other words, the packing scheme for
the mutated structure has been adjusted to accommo-
date the mutations. Also, as we have shown throughout,
the rearrangement primarily deals with changes in atom
volumes and vdW contacts. This appears to be driving
the conformational rearrangements.
Reshaping the HIV-1 Protease Active Site Cavity
around Residue 25
The next major difference is at residue D30 with a Ca de-
viation of 1.2 A˚. The residues from 23 through 32 form
the ‘‘floor’’ of the inhibitor binding cavity. The D30N mu-
tation confers resistance to nelfinavir, the L24I mutation
confers resistance to indinavir and lopinavir, and the
V32I mutation confers resistance to amprenavir, indina-
vir, lopinavir, and ritonavir (Johnson et al., 2003).
By ‘‘tracing the shifts’’ in the amino acid residues, we
can follow the effect all the way back to the mutation at
residue L90M. The insertion of the C3 of M90 into a small
pocket formed by residue 25 (which moves only slightly)
and G86-R87 forms several new vdW contacts that pre-
viously did not exist.
The new vdW interactions pull the main chain G86,
R87, and N88 closer in the direction of the M90 C3
atom. These residues, in turn, form backbone hydrogen
bonds from N88 N to D29 O, and from R87 N to A28 O,
drawing them in to include residue D30. An additional
side chain hydrogen bond between N88 OD1 and T31
N also helps ‘‘pull in’’ the D30 main chain. The impact
of the L90 mutation is cogent, since the leucine-to-
methionine mutation affects the efficacy of eight protease
inhibitor drugs, namely, amprenavir, fos-amprenavir,
atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and
saquinavir (Johnson et al., 2003). Thus, there is a domino
effect from the mutation of L90 that is 9.7 A˚ away from
MDR HIV-1 Protease Represents a Drug Target
1891D30 (Figure 6). The L90M mutation results in successive
perturbations via residues 86–88, leading to the reshap-
ing of the floor of the inhibitor binding cavity.
The Ca deviations were not only deviations at or near
the mutation points, but also in places that were at
some distance from the mutations. For example, residue
G16 moved more than 2 A˚ (2.2 A˚) relative to the wild-type
structure. Although the residue has good electron den-
sity, it has one of the highest B values of the structure
(Figure 1). The wild-type coordinate set used for com-
parison did not have refined B values. This could be
due to the low resolution of 3PHV and the flexibility of
the G16 region (Figure 1).
We observed that positions 16 and 17, the Gly-Gly res-
idues, deviate significantly between the two structures.
Upon closer inspection, we discovered that the large
movement at residue G16 is connected by a chain of
events because of the replacement of methionine 36
by valine and is a result of the propagation of mutational
changes. While the deviation is less for residues C67 and
G68, it is close enough to the 1 A˚ cutoff (C67 = 0.88 A˚
in chain A, C67 = 0.99 A˚ in chain B) that we believe that
the successive mutational reinforcement occurs here
as well.
Reshaping of the HIV-1 Protease Active Site Cavity
around Positions 82 and 84
Two key drug-resistance mutations are represented by
amino acid substitutions at positions 82 and 84, and
the patient isolate MDR 769 contains both of these mu-
tations (V82A and I84V). One important feature of MDR
Figure 6. L90M Influence on Chain Movement
Semitransparent spheres (yellow) represent the new van der Waals
contacts that develop between the L90M-CE atom and the G86-C
(3.6 A˚) and R87-CA (4.0 A˚) atoms. The resulting shifts in the back-
bone and side chains of MDR 769 (yellow) versus the wild-type
(green), as well as the new polar contacts that formed as a result
of this mutation, illustrate the changes that manifest themselves
via the domino effect.769 is that the V82A and I84V mutations cause an in-
crease in the volume of the active site cavity (Logsdon
et al., 2004), and the loss of a sigma carbon-carbon
bond results in an approximate change of 1.5 A˚ in each
of the 82, 182, 84 and 184 amino acid residues. Since
these four residues are in opposite corners of the active
site cavity, there is an approximate 3.0 A˚ expansion in-
side the active site.
A Water Scaffold Stabilizes the ‘‘Wide-Open’’
Active Site Cavity of the Multidrug-Resistant
HIV-1 Protease
The quality and resolution of this crystal structure al-
lowed us to determine the positions of 380 water mole-
cules surrounding the MDR 769 HIV-1 protease. Rather
than losing the stabilizing interchain hydrogen bonds
found in the wild-type ‘‘open’’ form, separated by more
than 12 A˚, the ordered water molecules provide stability
to the ‘‘wide-open’’ structure of the MDR protease. A
scaffold of hydrogen bonds has formed between the
ends of the flaps by intervening water molecules, adding
to the stabilization of the ‘‘wide-open’’ form (Figure 3).
About 100 water molecules from the total of 380 are lo-
cated in the active site cavity (Figure 7, upper panel),
and they form a scaffold in the active site cavity, pre-
venting the MDR HIV-1 protease from collapsing in the
absence of a ligand. The hydrogen bonding network
formed by about three layers of crystallographic waters
in the active site cavity is illustrated in the lower panel of
Figure 7. The replacement of the waters by an inhibitor
might be a logical step in designing protease inhibitors
against the MDR HIV.
Biologically Relevant Conformations
of the Crystal Form
While no one can either prove or disprove that any crys-
tal structure is the same as the solution structure, we
offer the following relevant points for consideration. Fig-
ure 8 illustrates the 769 MDR and wild-type HIV protease
dimers (standard CHNO colors) as space-filling models
to indicate the volume and contact area of these struc-
tures. The molecules that are in contact with the I50
loop by crystallographic symmetry are also shown
(gray). It is evident that a large cavity exists in the wild-
type structure (space group P41212) that very neatly ac-
cepts the MDR 769 I50-loop flaps in their new conforma-
tion (space group P41). With the unit cells between the
two structures very close to one another, basically
a crystallographic 2-fold along the diagonal in the wild-
type crystal has been replaced by a local 2-fold in the
mutant. Indeed, our latest mutants of MDR 769 (A82F,
A82S, and A82T) have all reverted back to space group
P41212 while still maintaining the ‘‘wide-open’’ format
and similar unit cell.
There is a lack of intermolecular hydrogen bonds in
this area in both structures. Both have a K55 N to Q92
OE1 hydrogen bond at 2.9 A˚. The wild-type has one ad-
ditional Q61 NE2 to G49 O hydrogen bond at 3.2 A˚. Note,
however, that these are all through flexible side chains.
MDR 769 does have additional flexible side chain hydro-
gen bonds: K55 NZ to T91 O (3.0 A˚), K55 NZ to G92 O
(3.3 A˚), Q92 NE2 to K55 O (2.9 A˚), and R41 NH2 (two
side chain conformations) to G48 O (2.5 A˚). Only one,
R41 N to G49 O (2.9 A˚), is a main chain hydrogen bond.
Structure
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Upper panel: Stereodiagram of water molecules shown in light blue in the active site cavity of the MDR HIV-1 protease. Lower panel: Stereo
diagram of the hydrogen bonding network (red color) formed by the water molecules in the active site cavity.We observe that intermolecular symmetry contacts
are made along stretches of chain that do not directly in-
volve mutated residues. They are, rather, adjacent to, or
in between (in the case of the I50 loop), these mutations.
We would propose that, since all of the surface residues
at which the symmetry contacts are made are present in
both structures, MDR 769 packs the way it packs be-
cause it is folded differently in the first place.
In general, we suggest that the controversy between
‘‘crystal structure’’ and ‘‘solution structure’’ cannot be
proved, except where physical evidence exists. Were
the solution structure significantly different from the
crystal structure, one would have to devise some as
yet unknown mechanism whereby a molecule would
have to somehow adopt the crystal conformation before
nucleation could occur. Once a nucleation event did oc-
cur, an additional unknown mechanism would need to
be devised to get the molecule being added to the grow-ing crystal surface, again, into the ‘‘crystal confor-
mation.’’ Or, we can simply say that the molecules in so-
lution are in the ‘‘crystal conformation’’ already, they
nucleate spontaneously when their solubility is de-
creased sufficiently by the precipitant, and they then
grow in the normal way.
However, while we favor the crystal structure as being
one of a possible collection of solution structures, there
is ample evidence that there can be conformational
states in crystals (DePristo et al., 2004). We cannot rule
out that the crystal structure is selected for from a num-
ber of solution conformations (Straub, 1964) that are in
rapid equilibrium with one another. We also distinguish
these from a ‘‘triggered’’ conformational change such
as occurs when a ligand (substrate or inhibitor) encoun-
ters the active site of an enzyme. These latter conforma-
tional states describe the transition from one equilibrium
conformation to another (Ringe and Petsko, 1986).Figure 8. Crystal Contact Comparisons be-
tween MDR 769 and the Wild-Type HIV-1 Pro-
tease
MDR 769 and the wild-type HIV protease
(standard colors) along with the molecules
that contact the I50 loop, which are related
by crystallographic-related symmetry (gray),
are shown. These mobile loops are seen to
fill a cavity in the wild-type structure (space
group P41212) and form different crystallo-
graphic contacts in the MDR 769 unit cell
(space group P41). The change in packing is
due to the multitude of small and large con-
formational differences between the two
structures, but it requires no significant
changes between the unit cells.
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when overlapped with a structure of a HIV protease con-
taining a peptide or drug (for example, wild-type HIV
with a peptidomimetic inhibitor, 1IIQ, or the mutant
V82A-L90M plus indinavir, 1SDT) undergo a consider-
able conformational change (not shown). Most of this
is at the I50 loop region and is an example of a ‘‘trig-
gered’’ conformational change.
It is accepted that proteins must ‘‘breathe’’ in order to
bind ligands such as substrates or inhibitors. Our ‘‘wide-
open’’ form of HIV protease is the only one that is open
enough for a substrate to enter the active site. Both
the wild-type structures and the drug bound structures
would require substances to enter the protease as if
threading through the eye of a needle.
The S2, S1, S10, and S20 sites of the HIV protease have
been mapped, and the peptides and drugs all span the
monomers of the dimer to which they bind. We would
like to propose the following mechanism. In order for
a drug to bind tightly, it might bind first to one monomer
(or the other) while it is in a ‘‘wide-open’’ conformation,
for example, in the P sites. The close proximity of the
drug extending into the P0 sites via electrostatic, hydro-
phobic, and hydrogen bonding interactions (Ringe and
Petsko, 1986) would then act as the ‘‘trigger’’ to close
the other monomer around the drug and bind it tightly.
In the MDR 769 structure, the geometry of the binding
cavity has been so drastically altered that the closure
does not occur. Also, the local geometry of each mono-
mer has also been altered, and the initial binding event
is probably not nearly as strong as with the wild-type
enzyme.
Experimental Procedures
Protease Expression and Purification
The MDR 769 protease was overexpressed by using a T7 promoter
expression vector in conjunction with the E. coli host, BL21(DE3). In
brief, a fresh transformant of BL21(DE3) with the MDR 769 plasmid
was cultured in 5 ml YT medium containing 100 mg/ml ampicillin to
an A600 of 0.5. At this point, the 5 ml culture was used to inoculate
a liter of YT medium with 100 mg/ml ampicillin. After 20 hr of incuba-
tion with shaking at 37ºC, these cells were harvested at 10,000 3 g
for 5 min at 4ºC by using a Sovall RC5B Plus centrifuge (Vickrey
et al., 2003).
The MDR protease was isolated from inclusion bodies by using
a series of buffered washes, followed by denaturing in 6 M urea.
For purification of the unfolded protease, an anion exchange resin
(Q Sepharose, Amersham Biosciences) was used that allowed the
protease to pass through and the contaminants to bind. The pro-
tease was determined to be purified greater than 95% through
Coomassie blue-stained SDS-PAGE (Laemmli, 1970).
The 6 M urea was removed to refold the protease by using a series
of dialysis exchanges that were carried out at 4ºC. The first four
buffer changes consisted of 40 mM sodium phosphate (pH 7),
0.2% bME, and 10% glycerol, and the last two buffer changes
were 10 mM sodium acetate, 1 mM DTT (pH 5). The protease was
concentrated to between 5 and 13 mg/ml for storage at 4ºC.
Protease Crystallization and Data Collection
The hanging drop vapor diffusion method was used to form the bi-
pyrimidal crystals of the MDR 769 protease. Using a matrix screen
consisting of pH (5.5 to 7.5) verses sodium chloride (0.3 to 0.9 M),
the HIV-1 protease crystals formed overnight at 22ºC. Routinely,
0.2 mm crystals in the longest dimension were obtained after
14 days of incubation.
Protease crystals were placed in a cryoprotectant consisting of
30% 400 PEG with the well solution and were frozen in liquid nitro-
gen, and data were collected at 1.00 A˚ wavelength at the AdvancedPhoton Source (APS) (IMCA-CAT beamline), Argonne National Lab-
oratory (Argonne, IL). Crystallographic data were collected at the
APS with an Oxford cryostream.
Data were reduced to structure amplitudes with HKL2000 (Otwi-
nowski and Minor, 1997). The data statistics are shown in Table 1.
Crystallographic refinement was initiated by the addition of solvent
to a model previously refined at a lower (1.8 A˚) resolution (Logsdon
et al., 2004) with 20 cycles of ARP/wARP (version 6.0, [Perrakis et al.,
1997]), as implemented in the CCP4 suite of programs (version 4.2.2,
[Fitzgerald, 1994]). The initial R and Rfree went from 0.313 and 0.335,
respectively, to 0.183 and 0.228, respectively. When done, the
Table 1. X-Ray Diffraction Data for MDR 769
Experimental Conditions
X-ray source APS (IMCA-CAT)
Wavelength (A˚) 1.0 A˚
Sample temperature 100 K
Crystal Parameters
Resolution range (A˚) 20–1.3
Unit cell (A˚) a = b = 45.04; c = 105.77
Space group P41
Mosaicity 0.3º
Percent solventa 42.7%
Data Processing
Number of unique reflections 42,456
Redundancy 4.50 (1.7)
I/s(I) 30.5 (1.5)
Completeness (%)b 82 (26)
Rsym
c (%) 4.3 (41.5)
a Computed based on SHELXL.
b Values in parentheses represent the numbers in the highest-reso-
lution shell.
c Rsym = S jI 2 <I>j/S I.
Table 2. Refinement Statistics for the 1.3 A˚ MDR 769 Structure
Refinement Parameters
Number of reflections used 38,356
Resolution range (A˚) 20–1.3
Number of protein atoms 1,562a
Number of water molecules 382
R Factors
Rcryst
b 0.14
Rfree
c 0.21
s cutoff none
<B> Average Atomic Temperature Factors (A˚2)
<B> Protein 20.50
<B> Side chains 23.46
<B> Main chains 17.62
<B> Solvent 35.83
Root-Mean-Square Deviations from Ideal Geometry
Bonds (A˚) 0.01
Atom1 to Atom3 distances (A˚) 0.03
Ramachandran Plot
Favorable (%) 94.2
Additional (%) 5.8
Generous (%) 0
Forbidden (%) 0
a The refinement statistics include residues in alternate conforma-
tions. The true number of protein atoms is 1508.
b Rcryst = S kFobsj 2 jFcalck/SjFobsj.
c Rfree = S kFobsj2 jFcalck/SjFobsj, where Fobs are test set amplitudes
(851 reflections) not used in refinement.
Structure
1894procedure had added 382 waters. At this point, the structure was ex-
amined graphically with XtalView (McRee, 1999), and alternate con-
formation side chains were added to the model.
At this time, we also noticed that the first two waters added to the
structure had unusual coordination properties. Rather than the four
(maximum for water) roughly tetrahedral ligands associated with
a typical hydrogen bonded water, these two had five ligands (a sixth
ligand position was occupied by a symmetry related carbon atom)
arranged in a roughly octahedral pattern (Figure 1). This is typical
of a metal ion rather than a water. Since sodium was the only metal
in the media (from the sodium acetate buffer), we concluded that this
was, indeed, a sodium ion, and it was included in the high-resolution
refinement.
Due to the high resolution (1.3 A˚), the data and coordinates were
ported into SHELXL (Sheldrick and Schneider, 1997), and the refine-
ment continued. A total of 15 cycles of isotropic refinement gave
R and Rfree values a bit higher (0.192 and 0.247, respectively) than
ARP/wARP, presumably from tighter restraints (38356 data [2071
data were used for Rfree], 7779 parameters). Full anisotropic refine-
ment for an additional 15 cycles (38356 data, 17,510 parameters)
lowered the R and Rfree to the final values of 0.142 and 0.211, respec-
tively. The lowering of Rfree by 3.6% showed that we were justified
in using anisotropic refinement at a data:parameter ratio of 2.2:1
(Table 2; 38,356 data and 17,519 parameters).
Ribbon diagrams were generated with PYMOL (DeLano, 2002)
and were polished with Adobe Photoshop, V7.0. Molecular cartoons
and electron density (CNS maps) were generated with SPOCK
(Christopher, 1998).
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